

10/657,910

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal621vx0

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAPLUS CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPLUS
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS	17	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS	18	JUN 18	DWPI: New coverage - French Granted Patents
NEWS	19	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS	20	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS	21	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAPLUS, CASREACT, and MARPAT
NEWS	22	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS	23	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years

10/923,271

of Biofuel Research Reveal China Now Atop U.S. in  
Patenting and Commercialization of Bioethanol  
NEWS 24 JUN 29 Enhanced Batch Search Options in DGENE, USGENE,  
and PCTGEN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:03:51 ON 18 JUL 2010

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.44	0.44

FILE 'REGISTRY' ENTERED AT 17:04:50 ON 18 JUL 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2010 HIGHEST RN 1232397-02-2  
DICTIONARY FILE UPDATES: 15 JUL 2010 HIGHEST RN 1232397-02-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

10/923,271


Uploading C:\Program Files\Stnexp\Queries\10657910a.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,N

G2 C,H,Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 17:06:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 206298 TO ITERATE

100.0% PROCESSED 206298 ITERATIONS

124 ANSWERS

SEARCH TIME: 00.00.05

L2 124 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

192.52

192.96

FILE 'CAPLUS' ENTERED AT 17:06:22 ON 18 JUL 2010

Toh

18/07/2010

10/923,271

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jul 2010 VOL 153 ISS 4  
FILE LAST UPDATED: 16 Jul 2010 (20100716/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12 and py<2004  
11 L2  
24051329 PY<2004  
L3 2 L2 AND PY<2004

=> d 1-2 ibib abs hitstr  
THE ESTIMATED COST FOR THIS REQUEST IS 11.62 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y


L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2004:964817 CAPLUS  
DOCUMENT NUMBER: 141:410756  
TITLE: Preparation of macrocyclic compounds for the treatment of inflammation and autoimmune disorders  
INVENTOR(S): Chiba, Kenichi; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Goto, Masaki; Gusovsky, Fabian; Harmange, Jean-Christophe; Inoue, Atsushi; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Matsushima, Tomohiro; Mizui, Yoshiharu; Muramoto, Kenzo; Sakurai, Hideki; Shen, Yong-chun; Shiota, Hiroshi; Spyvee, Mark; Tanaka, Isao; Wang, John; Wood, Ray; Yamamoto, Satoshi; Yoneda, Naoki  
PATENT ASSIGNEE(S): Japan  
SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of Appl. No. PCT/US03/07377.

10/923,271


CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040224936	A1	20041111	US 2003-657910	20030909
WO 2003076424	A1	20030918	WO 2003-US7377	20030307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
WO 2005023792	A2	20050317	WO 2004-US29196	20040909
WO 2005023792	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2008297317	A	20081211	JP 2008-194192	20080728
PRIORITY APPLN. INFO.:			US 2002-362883P	P 20020308
			US 2002-380711P	P 20020514
			WO 2003-US7377	A2 20030307
			JP 2003-574642	A3 20030307
			US 2003-657910	A 20030909

OTHER SOURCE(S): CASREACT 141:410756; MARPAT 141:410756  
GI



I



II

AB Macrocyclic compds. of formula I [R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R2, R3 = H, halo, (substituted) OH, alkyl, aryl, etc.; R1R2, R1R3 = alkylene; R4 = H, halo; R5 = H, protecting group, prodrug; R6, R7, R11 = H, (substituted) OH; R8, R9 = H, halo, (substituted) OH, alkoxy, etc.; R10 = H, (substituted) OH, (substituted) NH2; n = 0-2; X = absent, O, NH, N-alkyl, CH2, S; Y, Z = CH, O, CO, NH, etc.] are prepared for the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Thus, II was prepared in several steps. Some of the compds. inhibited NF- $\kappa$ B with IC50 values < 10 $\mu$ M.

IT 603039-45-8P 603045-38-1P 603045-40-5P  
 603045-42-7P 603045-44-9P 603045-46-1P  
 603151-24-2P 603151-32-2P 603151-34-4P  
 603959-45-1P 603985-37-1P 603985-63-3P  
 603985-65-5P 603985-69-9P 603985-71-3P  
 603985-72-4P 603985-73-5P 603985-74-6P  
 603985-75-7P 603985-77-9P 603985-78-0P  
 603986-04-5P 603987-34-4P 603987-35-5P  
 603987-75-3P 603987-93-5P 603988-36-9P  
 791101-13-8P 791101-14-9P 791101-15-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic compds. for the treatment of inflammatory or autoimmune disorders)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


10/923,271

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603045-40-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603045-42-7 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-  
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 603045-44-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-  
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603045-46-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603151-24-2 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




10/923,271



RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603959-45-1 CAPLUS

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-  
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-37-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-63-3 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

Chemical structure of compound 10, showing a benzene ring substituted with a methoxy group (MeO) and a hydroxyl group (OH). The benzene ring is connected via an ether linkage to a side chain containing a trans-alkene (E), a ketone group (C=O), and a cyclic sulfone ring with a methyl group (Me) and a hydroxyl group (OH).

CN Acetamide, N-[3-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)


CN Acetamide, N-[3-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

18/07/2010

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(  
(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-72-4 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-73-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-  
pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


10/923,271



RN 603985-74-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



=O

RN 603985-77-9 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-  
 ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




=O

RN 603985-78-0 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.

10/923,271




RN 603986-04-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-  
trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603987-34-4 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methoxycarbonyl)-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603987-35-5 CAPLUS

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603987-75-3 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603987-93-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-  
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




10/923,271




RN 603988-36-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-  
dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 791101-13-8 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 791101-14-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(methylamino)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 791101-15-0 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:737744 CAPLUS

DOCUMENT NUMBER: 139:261090

TITLE: Preparation of macrocyclic compounds for use in  
pharmaceutical and cosmetic compositions which  
regulate various genes involved in immune and  
inflammatory responses


INVENTOR(S): Boivin, Roch; Chiba, Kenichi; Davis, Heather A.;  
Diepitro, Lucian; Du, Hong; Eguchi, Yoshihito; Fujita,  
Masanori; Gilbert, Sandra; Goto, Masaki; Harmange,  
Jean Christophe; Inoue, Atsushi; Jiang, Yimin; Kawada,

Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Lemelin, Charles; Li, Xiang-yi; Matsushima, Tomohiro; Mizui, Yoshiharu; Sakurai, Hideki; Schiller, Shawn; Shen, Yongchun; Spyvee, Mark; Tanaka, Isao; Wang, Yuan; Yamamoto, Satoshi; Yoneda, Naoki; Kobayashi, Seiichi  
 PATENT ASSIGNEE(S): Eisai Co. Ltd., Japan; et al.  
 SOURCE: PCT Int. Appl., 438 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076424	A1	20030918	WO 2003-US7377	20030307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478065	A1	20030918	CA 2003-2478065	20030307 <--
AU 2003224672	A1	20030922	AU 2003-224672	20030307 <--
AU 2003224672	B2	20100204		
BR 2003008113	A	20050209	BR 2003-8113	20030307
EP 1507773	A1	20050223	EP 2003-721353	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519954	T	20050707	JP 2003-574642	20030307
CN 1653059	A	20050810	CN 2003-810248	20030307
NZ 535101	A	20070727	NZ 2003-535101	20030307
RU 2334744	C2	20080927	RU 2004-129755	20030307
US 20040224936	A1	20041111	US 2003-657910	20030909
IN 2004KN01270	A	20060714	IN 2004-KN1270	20040830
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
MX 2004008722	A	20050713	MX 2004-8722	20040908
NO 2004004256	A	20041207	NO 2004-4256	20041007
US 20060247448	A1	20061102	US 2004-507067	20041110
JP 2008297317	A	20081211	JP 2008-194192	20080728
AU 2010201776	A1	20100527	AU 2010-201776	20100504
PRIORITY APPLN. INFO.:			US 2002-362883P	P 20020308
			US 2002-380711P	P 20020514
			AU 2003-224672	A3 20030307
			JP 2003-574642	A3 20030307
			WO 2003-US7377	W 20030307

OTHER SOURCE(S): MARPAT 139:261090  
 GI



AB Macrocyclic lactones and lactams, such as I [R1 = H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R2, R3 = H, OH, halogen, protected hydroxyl, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2 or R1R3 = 3-8 membered alicyclic ring; R4 = H, halogen; R5 = H, hydroxyl protecting group, linked prodrug; R6, R7 = H, OH, protected hydroxyl; R8, R9, R10, R11 = H, OH, NH<sub>2</sub>, alkoxy, alkylamino, etc.; X = O, NH, S, CH<sub>2</sub>, etc.; R8R9 = fused ring, such as furan or imidazole; Y-Z = CH:CH, NHCO, etc.], were prepared for a variety of therapeutic and cosmetic uses, such as antitumor and anti-inflammatory agents and treatment of skin photodamage. These macrocycles are claimed for use as NF- $\kappa$ B, AP-1, protein kinase, cancer cell proliferation and solid tumor angiogenesis inhibitors and for use in the treatment of inflammation, cancer, psoriasis, skin photodamage, restenosis as stent coatings, rheumatoid arthritis, asthma, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, autoimmune disorders and for treatment of gastrointestinal, esophageal, tracheal/bronchial, urethral and vascular obstructions wherein the lumen of a body passageway is expanded. Thus, macrocyclic lactone II, designated as ER 803064, was prepared via a multistep synthetic sequence with included a macrolactonization reaction of III to form the desired lactone ring. The prepared macrocycles were assayed for their effect on TNF- $\alpha$  and  $\beta$ -actin placental alkaline phosphatase transcription using human acute monocytic leukemia cells.

IT 791101-13-8 1080810-60-1 1080810-61-2  
 1080810-62-3 1080810-64-5 1080810-65-6  
 1080810-66-7 1080810-68-9 1080810-70-3  
 1080810-71-4 1080810-72-5 1080810-73-6  
 1080810-74-7 1080810-75-8 1080810-76-9  
 1080810-77-0 1080810-78-1 1080810-79-2

10/923,271

1080810-80-5	1080810-81-6	1080810-82-7
1080810-83-8	1080810-84-9	1080810-85-0
1080810-86-1	1080810-87-2	1080810-88-3
1080810-89-4	1080810-90-7	1080810-91-8
1080810-92-9	1080810-93-0	1080810-95-2
1080810-96-3	1080810-97-4	1080810-98-5
1080810-99-6	1080811-01-3	1080811-02-4
1080811-03-5	1080811-04-6	1080811-05-7
1080811-06-8	1080811-07-9	1080811-08-0
1080811-09-1	1080811-10-4	1080811-11-5
1080811-12-6	1083006-06-7	1198575-07-3


RL: PRPH (Prophetic)

(Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses)

RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-60-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-61-2 CAPLUS

10/923,271

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-62-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-64-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080810-65-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-66-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-68-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080810-70-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-71-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-72-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as described by E or Z.






10/923,271


RN 1080810-73-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-74-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-75-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080810-76-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-77-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-78-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080810-79-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-80-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-81-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-A




RN 1080810-82-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.





RN 1080810-83-8 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(1H-1,2,3-triazol-  
1-yl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-84-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-85-0 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 1080810-86-1 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
 Double bond geometry as shown.

10/923,271



RN 1080810-87-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as described by E or Z.



RN 1080810-88-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A






RN 1080810-89-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-90-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080810-91-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-92-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-93-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.






10/923,271


RN 1080810-95-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-96-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-97-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080810-98-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-99-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-01-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080811-02-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-03-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-04-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.

10/923,271




RN 1080811-05-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-06-8 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-butoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080811-07-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(1-methylethoxy)-,

10/923,271


(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080811-08-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-09-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



10/923,271


RN 1080811-10-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as described by E or Z.




RN 1080811-11-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-12-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.




10/923,271

RN 1083006-06-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1198575-07-3 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4,4-dimethyl-,  
(5Z,8S,9S,11E)- (CA INDEX NAME)




IT 603044-46-8P 603045-38-1P 603045-40-5P  
603045-42-7P 603045-44-9P, ER 807563  
603045-45-0P 603045-46-1P 603151-24-2P, ER  
803064 603151-32-2P 603151-34-4P, ER 804019  
603959-46-2P, ER 804035 603985-37-1P  
603985-63-3P 603985-64-4P 603985-65-5P  
603985-69-9P 603985-70-2P, ER 804606  
603985-72-4P 603985-73-5P 603985-74-6P  
603985-75-7P 603985-76-8P 603985-77-9P  
603985-78-0P 603986-04-5P, ER 804387  
603987-34-4P 603987-35-5P 603987-75-3P  
603987-93-5P, ER 806821 603988-36-9P  
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic  
compns. which regulate various genes involved in immune and  
inflammatory responses)  
RN 603044-46-8 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-

10/923,271


(methylamino)-, (3S,4R,5E,8R,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603045-38-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603045-40-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




10/923,271



RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-  
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-  
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603045-45-0 CAPLUS

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-  
[(methylsulfonyl)oxy]propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603045-46-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603151-24-2 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


10/923,271



RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603959-46-2 CAPLUS

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4-methyl-,  
(4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-37-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-63-3 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


10/923,271



RN 603985-64-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-65-5 CAPLUS

CN Acetamide, N-[3-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-  
trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-  
oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603985-69-9 CAPLUS

10/923,271


CN Acetamide, N-[3-[[ (3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-70-2 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-72-4 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

10/923,271




RN 603985-73-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-  
pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-74-6 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603985-75-7 CAPLUS

10/923,271

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-  
ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX  
NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



=O

RN 603985-76-8 CAPLUS  
CN Methanesulfonamide, N-[2-[[ (3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-  
8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-  
yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603985-77-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-  
ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX  
NAME)



10/923,271


Absolute stereochemistry.  
Double bond geometry as shown.



$\text{=O}$

RN 603985-78-0 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603986-04-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-  
trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


10/923,271



RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603987-75-3 CAPLUS

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603987-93-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-  
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603988-36-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-  
dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

10/923,271



IT 603039-45-8P 603959-45-1P 603985-71-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic  
compns. which regulate various genes involved in immune and  
inflammatory responses)  
RN 603039-45-8 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-  
(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603959-45-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-  
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

10/923,271



RN 603985-71-3 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-  
(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(7 CITINGS)  
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT